NCT06756035RecruitingPhase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 18 Dec 2024
- Start date
- 31 Mar 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Context Therapeutics Inc.
- Diseases
- Mesothelioma, Lung cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Ovarian cancer
- NCT number
- NCT06756035
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 70
- From 31 Mar 2025 to the primary completion date, Dec 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
- Concurrent participation in another investigational clinical trial.
Other illness
- Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
- Evidence of leptomeningeal disease
Who the study is looking for
- ECOG 0 or 1
- Subjects with evaluable disease per RECIST 1.1 or mRECIST
- Subjects with adequate organ function.
- Subjects with advanced cancers associated with mesothelin expression
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Denver | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Grand Rapids | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Hackensack | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.